Caplacizumab improves clinical outcomes and is well tolerated across clinically relevant subgroups of patients with immune-mediated thrombotic thrombocytopenic purpura
Titel:
Caplacizumab improves clinical outcomes and is well tolerated across clinically relevant subgroups of patients with immune-mediated thrombotic thrombocytopenic purpura
Auteur:
Pavenski, Katerina Scully, Marie Coppo, Paul Cataland, Spero Knöbl, Paul Peyvandi, Flora Kremer Hovinga, Johanna A. de la Rubia, Javier Khan, Umer Marques, Ana Paula Gunawardena, Sriya
Verschenen in:
Research and practice in thrombosis and haemostasis